Editorial intelligence brief
Announced an AstraZeneca AI drug-discovery collaboration on October 15, 2026, with $40M upfront and up to about $1.46B in contingent milestones.
Focus: Causal AI and machine learning for therapeutic target discovery and drug design
Latest funding
Not tracked
No structured event
Tracked funding
Not tracked
No structured events
Latest valuation
Not tracked
No source-backed record
Latest revenue
Not tracked
Growth lifecycle position
Editorially verified updates
The October 15 collaboration includes $40M upfront and eligibility for up to about $1.46B in contingent milestones plus possible royalties; the larger figure is not guaranteed funding.
Selected by relevance, date and publisher; grouped by story. External reporting is not independently verified by the map. Article dates are publisher timestamps supplied by the discovery feed; quieter profiles may show coverage up to 90 days old.
Last checked Oct 19, 2026.
Reuters · Reporting
Oct 15, 2026
WSJ · Reporting
Oct 15, 2026
Source-backed financial history
Funding, valuation, revenue, and debt are kept separate so unlike measurements are never presented as one trend.
A structured financial history has not been completed for insitro.
The profile will not manufacture a trend from incomplete or unsourced figures. Each amount must be dated, typed, and linked to public evidence first.
Product surface
Recent models
No standalone model family is structured for this profile.
Products
Open weights
No
API access
No
Review target
Weekly
Market position
Research
Preview
Growth
Deployment
Growth: Public access & scaling
Focus
Causal AI and machine learning for therapeutic target discovery and drug design
Signals
Taxonomy
Competitive context
Infrastructure & distribution
Model layer
No standalone model family tracked
Access layer
Application or managed product
Market layer
Vertical + Enterprise
Public product surface
Stack signals
This section reflects publicly visible product and access signals. Undisclosed GPU, cloud, training, and data-center contracts are not inferred.
Evidence trail
Primary and public sources used to verify the structured company profile.
The Staticbreaker
The Staticbreaker turns launches, category shifts, and market noise into a concise editorial briefing.
